.RESEARCH HIGHLIGHT.06 August 2024.
A large randomized measured trial with cisgender girls highlights the obstacles of adherence to a daily oral preexposure prevention routine and shows that twice-yearly injection of lenacapavir may maintain helpful HIV prevention amounts over 6 months.